551 Pegasus Skin, a study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL2) with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers

BackgroundSAR444245 (THOR-707) is a recombinant human IL-2 molecule that includes a PEG moiety irreversibly bound to a novel amino acid via click chemistry to block the alpha-binding domain while retaining near-native affinity for the beta/gamma subunits. In animal models, SAR444245 showed anti-tumor benefits, but with no severe side effects, both as single agent and when combined with anti-PD1 comparing with historical data from aldesleukin. The HAMMER trial, which is the FIH study, shows preliminary encouraging clinical results: initial efficacy and safety profile with SAR444245 monotherapy and in combination with pembrolizumab supporting non-alpha preferential activity, validating preclinical models. The Pegasus Skin Phase 1/2 study will evaluate the clinical benefit of SAR444245 in combination with cemiplimab (anti-PD1) for the treatment of participants with cutaneous squamous cell carcinoma (CSCC) or melanomaMethodsPegasus Skin (NCT04913220) will enroll approximately 80 participants in 2 separate cohorts. In cohort A, participants with a locally advanced, unresectable or metastatic melanoma will receive SAR444245 + cemiplimab as first line (1L) therapy. In cohort B, participants with locally advanced or metastatic CSCC who have not received moe than 2 prior lines of systemic therapy and are not candidates for curative surgery or radiation will receive SAR444245 + cemiplimab. The study will start with a dose escalation to determine the recommended phase 2 dose (RP2D) of SAR444245 when combined with cemiplimab. The starting dose will be 16 μg/kg Q3W (DL1) with a possibility to de-escalate to 8 μg/kg Q3W (DL -1) or escalate to 24 μg/kg Q3W (DL2) based on the occurrence of DLT and overall assessment of safety. Participants enrolled in the Dose Escalation and treated at the RP2D selected for Dose Expansion will be included in the total number of participants for efficacy and safety evaluation. Participants will receive study treatment until disease progression, unacceptable toxicity, or completion of 35 cycles. Cemiplimab will be administered 350 mg per label, Q3WAcknowledgementsThe Pegasus Skin study is sponsored by SanofiTrial RegistrationNCT04913220Ethics ApprovalAll applicable ECs are obtainedConsentAll participant consents are obtaine

Le FORUM, Vol. 32 Nos. 1 & 2

https://digitalcommons.library.umaine.edu/francoamericain_forum/1020/thumbnail.jp

Le FORUM, Vol. 32 Nos. 3 & 4

https://digitalcommons.library.umaine.edu/francoamericain_forum/1021/thumbnail.jp

Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma : Phase 2 study

The poor prognosis of acute T-cell lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in older adults and patients with relapsed/refractory illness is an unmet clinical need, as there is no defined standard of care and there are few treatment options. Abnormally elevated CD38 expression in T-ALL and T-LBL is associated with tumor expansion and disease development, making CD38 a potential target for anti-T-ALL and T-LBL treatment. Isatuximab is a monoclonal antibody that binds to a specific epitope on CD38. The purpose of the study was to assess the efficacy and safety of isatuximab monotherapy in a phase 2, multicenter, one-arm, open-label study in patients with relapsed or refractory T-ALL or T-LBL (Clinical Trials.gov identifier NCT02999633). The primary endpoint was to assess the efficacy of isatuximab by overall response rate (ORR). An interim analysis based on the efficacy and safety of isatuximab in the first 19 patients enrolled was scheduled, however only 14 patients were enrolled in the study. No patient achieved complete response (CR) or CR with incomplete peripheral recovery. Most patients (11 [78.6%]) developed progressive disease and had progressive disease as their best response. A total of 10 (71.4%) patients had treatment emergent adverse events considered treatment-related, with infusion reactions as the most frequent drug-related TEAE, occurring in 8 (57.1%) patients. Despite the low efficacy of isatuximab in the current study, it is likely that the use of immunotherapy medication in T-ALL will be expanded through logically targeted approaches, together with advances in the design of T-cell therapy and clinical experience and will provide restorative options beyond chemotherapy and targeted treatments.Peer reviewe

The global burden of injury: Incidence, mortality, disability-adjusted life years and time trends from the global burden of disease study 2013

Background The Global Burden of Diseases (GBD), Injuries, and Risk Factors study used the disabilityadjusted life year (DALY) to quantify the burden of diseases, injuries, and risk factors. This paper provides an overview of injury estimates from the 2013 update of GBD, with detailed information on incidence, mortality, DALYs and rates of change from 1990 to 2013 for 26 causes of injury, globally, by region and by country. Methods Injury mortality was estimated using the extensive GBD mortality database, corrections for illdefined cause of death and the cause of death ensemble modelling tool. Morbidity estimation was based on inpatient and outpatient data sets, 26 cause-of-injury and 47 nature-of-injury categories, and seven follow-up studies with patient-reported long-term outcome measures. Results In 2013, 973 million (uncertainty interval (UI) 942 to 993) people sustained injuries that warranted some type of healthcare and 4.8 million (UI 4.5 to 5.1) people died from injuries. Between 1990 and 2013 the global age-standardised injury DALY rate decreased by 31% (UI 26% to 35%). The rate of decline in DALY rates was significant for 22 cause-of-injury categories, including all the major injuries. Conclusions Injuries continue to be an important cause of morbidity and mortality in the developed and developing world. The decline in rates for almost all injuries is so prominent that it warrants a general statement that the world is becoming a safer place to live in. However, the patterns vary widely by cause, age, sex, region and time and there are still large improvements that need to be made

Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

BACKGROUND: Measurement of changes in health across locations is useful to compare and contrast changing epidemiological patterns against health system performance and identify specific needs for resource allocation in research, policy development, and programme decision making. Using the Global Burden of Diseases, Injuries, and Risk Factors Study 2016, we drew from two widely used summary measures to monitor such changes in population health: disability-adjusted life-years (DALYs) and healthy life expectancy (HALE). We used these measures to track trends and benchmark progress compared with expected trends on the basis of the Socio-demographic Index (SDI). METHODS: We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 for all-cause mortality, cause-specific mortality, and non-fatal disease burden to derive HALE and DALYs by sex for 195 countries and territories from 1990 to 2016. We calculated DALYs by summing years of life lost and years of life lived with disability for each location, age group, sex, and year. We estimated HALE using age-specific death rates and years of life lived with disability per capita. We explored how DALYs and HALE differed from expected trends when compared with the SDI: the geometric mean of income per person, educational attainment in the population older than age 15 years, and total fertility rate. FINDINGS: The highest globally observed HALE at birth for both women and men was in Singapore, at 75·2 years (95% uncertainty interval 71·9-78·6) for females and 72·0 years (68·8-75·1) for males. The lowest for females was in the Central African Republic (45·6 years [42·0-49·5]) and for males was in Lesotho (41·5 years [39·0-44·0]). From 1990 to 2016, global HALE increased by an average of 6·24 years (5·97-6·48) for both sexes combined. Global HALE increased by 6·04 years (5·74-6·27) for males and 6·49 years (6·08-6·77) for females, whereas HALE at age 65 years increased by 1·78 years (1·61-1·93) for males and 1·96 years (1·69-2·13) for females. Total global DALYs remained largely unchanged from 1990 to 2016 (-2·3% [-5·9 to 0·9]), with decreases in communicable, maternal, neonatal, and nutritional (CMNN) disease DALYs offset by increased DALYs due to non-communicable diseases (NCDs). The exemplars, calculated as the five lowest ratios of observed to expected age-standardised DALY rates in 2016, were Nicaragua, Costa Rica, the Maldives, Peru, and Israel. The leading three causes of DALYs globally were ischaemic heart disease, cerebrovascular disease, and lower respiratory infections, comprising 16·1% of all DALYs. Total DALYs and age-standardised DALY rates due to most CMNN causes decreased from 1990 to 2016. Conversely, the total DALY burden rose for most NCDs; however, age-standardised DALY rates due to NCDs declined globally. INTERPRETATION: At a global level, DALYs and HALE continue to show improvements. At the same time, we observe that many populations are facing growing functional health loss. Rising SDI was associated with increases in cumulative years of life lived with disability and decreases in CMNN DALYs offset by increased NCD DALYs. Relative compression of morbidity highlights the importance of continued health interventions, which has changed in most locations in pace with the gross domestic product per person, education, and family planning. The analysis of DALYs and HALE and their relationship to SDI represents a robust framework with which to benchmark location-specific health performance. Country-specific drivers of disease burden, particularly for causes with higher-than-expected DALYs, should inform health policies, health system improvement initiatives, targeted prevention efforts, and development assistance for health, including financial and research investments for all countries, regardless of their level of sociodemographic development. The presence of countries that substantially outperform others suggests the need for increased scrutiny for proven examples of best practices, which can help to extend gains, whereas the presence of underperforming countries suggests the need for devotion of extra attention to health systems that need more robust support. FUNDING: Bill & Melinda Gates Foundation

Peptide‐Conjugated Silver Nanoparticles for the Colorimetric Detection of the Oncoprotein Mdm2 in Human Serum

The development of efficient, reliable, and easy-to-use biosensors allowing early cancer diagnosis is of paramount importance for patients. Herein, we report a biosensor based on silver nanoparticles functionalized by peptide aptamers for the detection of a cancer biomarker, i.e. the Mdm2 protein. Silver nanoparticles (AgNPs) were produced and stabilized with a thin PEGylated-calix[4]arene layer that allows (i) the steric stabilization of the AgNPs and (ii) the covalent conjugation of the peptide aptamers via the formation of an amide bond. These peptide-conjugated AgNPs were then used to detect Mdm2 via a dual trapping strategy that was previously reported with gold nanoparticles (AuNPs). Our results showed that replacing AuNPs by AgNPs allows to improve the detection limit by nearly one order of magnitude, down to 5 nM, while the high selectivity of the system and the stability of the particles provided by the calixarene coating allow the detection of Mdm2 in human serum.info:eu-repo/semantics/publishe

« Présence/absence» ou l’art de faire parler les aires d’ensilage et les rejets détritiques à défaut de structures d’habitat à partir du site de Milly-la-Forêt, «Le Bois Rond»/Carrière Fulchiron (Essonne) : un habitat ouvert de la période transitoire Hallstatt final/La Tène ancienne

National audienc